Clinical trials: Aspergillus Infection
Candidiasis, Fungal Infection
PTX3-targeted Antifungal Prophylaxis
This is a prospective genetically-stratified randomized double-blind event-driven multicentre clinical trial to assess the efficacy of posaconazole-based antifungal prophylaxis allocation strategies for patients with acute…
- Conditions
- Candidiasis, Fungal Infection, Acute Myeloid Leukemia, Genetic Predisposition
- Trial name
- PTX3AML (NCT03828773)
- Testing
- Posaconazole, Fluconazole
- Where
- 9 sites in Belgium, France and 1 more
- Volunteers
- 410 people
- Sponsor
- Bochud Pierre-Yves
Aspergillosis
Trial of Micafungin (FK463) in Combination With Liposomal Amphotericin B (AmBisome) for Aspergillosis
The purpose of this study is to evaluate the safety and effectiveness of micafungin in combination with AmBisome as first-line therapy in the treatment of invasive aspergillosis.
- Trial name
- NCT00047827
- Testing
- Micafungin, Liposomal Amphotericin B
- Where
- 7 sites in United States
- Volunteers
- 2 people
- Sponsor
- Astellas Pharma Inc
Candidemia, Mycoses
Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation
The purpose of this pivotal study is to determine if intravenous Rezafungin is efficacious and safe in the prevention of invasive fungal diseases when compared to the standard antimicrobial regimen.
- Conditions
- Candidemia, Mycoses, Fungal Infection, Fungemia
- Trial name
- ReSPECT (NCT04368559)
- Testing
- Rezafungin for Injection, Posaconazole, Fluconazole
- Where
- 53 sites in United States, Belgium and 7 more
- Volunteers
- 602 people
- Sponsor
- Mundipharma Research Limited
Invasive Aspergillosis
Study of Potential for Interaction of Fluconazole With F901318
This will be an open label study in two parts. In the first part, F901318 (dose 2 mg/kg IV over 4 hours, Day 1) will be followed by F901318 (2 mg/kg IV over 4 hours) given on Day 8, after dosing with fluconazole 800 mg daily for…
- Trial name
- NCT02730442
- Testing
- F901318, Fluconazole
- Where
- United Kingdom
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- F2G Ltd
Invasive Aspergillosis
Posaconazole (MK-5592) Intravenous and Oral in Children With Invasive Aspergillosis (IA) (MK-5592-104)
This study will evaluate the safety, efficacy, and pharmacokinetics of posaconazole (POS) intravenous (IV) and oral formulations in pediatric participants 2 to <18 years of age with invasive aspergillosis (IA).
- Trial name
- NCT04218851
- Testing
- Posaconazole IV, Posaconazole PFS, Posaconazole tablet
- Where
- 29 sites in United States, Belgium and 8 more
- Volunteers
- 31 people
- Sponsor
- Merck Sharp & Dohme LLC
Aspergillosis
Trial of Combination Antifungal Therapy (Vori+Mica vs. Vori+Placebo) in Invasive Aspergillosis
The purpose of this study is to evaluate the therapeutic effectiveness of combination antifungal therapy (CAT) of voriconazole plus micafungin versus voriconazole plus placebo equivalent as primary therapy for invasive…
- Trial name
- NCT01207128
- Testing
- Voriconazole, micafungin
- Where
- 2 sites in United States
- Sponsor
- University of Arkansas
Invasive Candidiasis, Mucocutaneous Candidiasis
Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment
This is a multicenter, open label, non-comparator, single arm study to evaluate the efficacy and safety of ibrexafungerp (SCY-078) in patients ≥ 18 years of age with a documented fungal disease that has been intolerant or…
- Conditions
- Invasive Candidiasis, Mucocutaneous Candidiasis, Coccidioidomycosis, Histoplasmosis
- Trial name
- FURI (NCT03059992)
- Testing
- Ibrexafungerp
- Where
- 37 sites in United States, Austria and 6 more
- Volunteers
- 233 people
- Sponsor
- Scynexis, Inc.
Aspergillosis Invasive, Fungal Infection
Individualized First Maintenance Doses of Voriconazole Through a Multiparametric Algorithm
The goal of this interventional single-arm study is to evaluate the interest of a multiparametric algorithm for individualization of first voriconazole maintenance doses for improvement of initial voriconazole exposure in adult…
- Conditions
- Aspergillosis Invasive, Fungal Infection, Hematologic Malignancy
- Trial name
- VORIPRECI (NCT06582186)
- Testing
- Individualization of first voriconazole maintenance doses
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Grenoble
Mycoses
Study of Posaconazole in the Treatment of Invasive Fungal Infections (Study P02095)
This study is designed to evaluate the safety, tolerance and efficacy of Posaconazole (SCH 56592) under an open label, treatment protocol for subjects with invasive fungal infections: A.
- Trial name
- NCT00034632
- Testing
- Posaconazole oral suspension
- Sponsor
- Merck Sharp & Dohme LLC
Aspergillosis Invasive, Mucormycosis
Study on Theraputic Drug Monitoring and Phamacokinetics of Isavuconazole in Children
The goal of this clinical trial is to learn the plasma concentration of isavuconazole in pediatric patients. It will also learn about the relationship of isavuconazole plasma concentrations to efficacy and safety in pediatric…
- Trial name
- NCT06440915
- Testing
- Theraputic drug monitoring, Isavuconazole
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Shanghai Children's Medical Center
Aspergillosis, Lung Transplant Infection
The Effect of Early Treatment of PC945 on Aspergillus Fumigatus Lung Infection in Lung Transplant Patients.
This study tests the effects of pre-emptive treatment with an experimental drug PC945 in lung transplant recipients whose lungs are infected by the fungus Aspergillus fumigatus.
- Trial name
- NCT03905447
- Testing
- PC945, Standard of Care
- Where
- 3 sites in United Kingdom
- Volunteers
- 2 people
- Sponsor
- Pulmocide Ltd
Fever, Mycoses
Phase I Study of the Safety, Tolerance, and Pharmacokinetics of FK463 in Immunocompromised Children With Fever and Neutropenia
The objective of this study is to evaluate the safety, tolerance, and pharmacokinetics of FK463, a novel echinocandin (cell wall-active antifungal lipopeptide), as early empirical therapy for prevention of fungal infections in…
- Conditions
- Fever, Mycoses, Neutropenia
- Trial name
- NCT00001790
- Testing
- FK463
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- National Cancer Institute (NCI)
Aspergillosis, Invasive Pulmonary
PCR Based Detection of Azole Resistance in A. Fumigatus to Improve Patient Outcome.
A standard treatment protocol for invasive aspergillosis (IA) will be implemented in several academic hematology centers in the Netherlands in which a diagnostic test demonstrating azole resistance by multiplex real-time…
- Trial name
- AzorMan (NCT03121235)
- Testing
- PCR based detection of azole resistance in A. fumigatus
- Where
- 8 sites in Netherlands
- Volunteers
- 320 people
- Sponsor
- Erasmus Medical Center
Fungal Infections, Invasive Pulmonary Aspergillosis
A Study of the Safety and Efficacy of Posaconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis (MK-5592-069)
The purpose of this study is to evaluate the safety and efficacy of posaconazole (POS) versus voriconazole (VOR) in the treatment of adults and adolescents with invasive aspergillosis (IA).
- Trial name
- NCT01782131
- Testing
- Posaconazole, Voriconazole
- Volunteers
- 585 people
- Sponsor
- Merck Sharp & Dohme LLC
Invasive Pulmonary Aspergillosis
Value of Amphotericin B Inhalation for Prophylaxis of Invasive Pulmonary Aspergillosis After Renal Transplantation
The purpose of this study is to determine whether inhalation with aerosolized amphoterin B 10mg/d is more effective than aerosolized amphoterin B 2mg/d to reduce the incidence of invasive pulmonary aspergillosis.
- Trial name
- NCT00986713
- Testing
- Amphotericin B
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Capital Medical University
Invasive Pulmonary Aspergillosis
Non-invasive Tools to Diagnose Invasive Aspergillosis Infections in ICU Patients With COVID-19 and Other Conditions.
Invasive aspergillosis (IA) are difficult to diagnose in the ICU population, as the patients often do not present the conventional risks factors of immunocompromised patients (EORTC/MSG criteria).
- Trial name
- BM-ASP-ICU (NCT05138666)
- Testing
- respiratory sample, blood sample
- Where
- France
- Volunteers
- 363 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Allergic Bronchopulmonary Aspergillosis
Evaluation of a Therapeutic Strategy Including Nebulised Liposomal Amphotericin B (Ambisome®) in Maintenance Treatment of Allergic Bronchopulmonary Aspergillosis (Cystic Fibrosis Excluded).
Compare the incidence of severe clinical exacerbations in the treatment of ABPA, between a strategy with a maintenance treatment and a conventional strategy without antifungal maintenance therapy.
- Trial name
- NEBULAMB (NCT02273661)
- Testing
- Liposomal amphotericin B (Ambisome®)
- Where
- France
- Volunteers
- 174 people
- Sponsor
- Poitiers University Hospital
Systemic Mycosis
Voriconazole (Vfend) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)
To collect the efficacy and safety informations of voriconazole related to their appropriate use in daily practice.
- Trial name
- NCT01151085
- Testing
- Voriconazole
- Volunteers
- 1,002 people
- Sponsor
- Pfizer
Invasive Aspergillosis
Evaluation of the Potential for Cytochrome P450 3A4 Inhibition by F901318 Using Oral Midazolam as a Probe
Open label evaluation of potential interaction of F901318 with cytochrome P450 3A4 using midazolam as a probe. Twenty healthy male subjects will participate
- Trial name
- NCT02680808
- Testing
- Midazolam with F901318
- Where
- United Kingdom
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- F2G Ltd
Influenza With Pneumonia, Aspergillosis Invasive
Invasive Pulmonary Aspergillosis Complicating Influenza Infection
Study the incidence and outcome of invasive pulmonary aspergillosis (IPA) in ICU patients with severe influenza and in influenza-negative control patients with severe community-acquired pneumonia
- Trial name
- NCT03391492
- Where
- 2 sites in Belgium
- Volunteers
- 298 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven